Search | Clinical Trials Finder

Conditions: Metastatic Pancreas Adenocarcinoma
Interventions: 5FU, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 7
States / cities: Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 4 more

Conditions: Cancer
Interventions: E7389 + carboplatin AUC 5, E7389+carboplatin AUC 6; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more

Conditions: Advanced Solid Tumor or Lymphoma
Interventions: BJ-005; Biological
Lead sponsor: BJ Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Jacksonville, Florida • Port Saint Lucie, Florida + 3 more

Conditions: Ulcerative Colitis
Interventions: Mirikizumab SC, Mirikizumab IV, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 57
States / cities: Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more

Conditions: Relapsed/Refractory Philadelphia Positive B-precursor ALL
Interventions: Blinatumomab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Duarte, California • La Jolla, California • Atlanta, Georgia + 5 more

Conditions: Cardiac Sarcoidosis
Interventions: 11C-PBR PET; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Prostate Cancer
Interventions: Samarium Sm 153 lexidronam pentasodium, Sargramostim, Recombinant vaccinia-TRICOM vaccine, Recombinant fowlpox-TRICOM vaccine; Radiation · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Chicago, Illinois • Bethesda, Maryland • New Brunswick, New Jersey

Conditions: Pain
Interventions: lidocaine, Placebo; Drug
Lead sponsor: Drexel University College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neoplasm Metastasis
Interventions: XMT-1107; Drug
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee

Conditions: Endometriosis, Post Operative Pain
Interventions: Ketamine, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Adipose Derived Stem Cell (ADSC) Therapy; Drug
Lead sponsor: Kimera Society Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Davie, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more

Conditions: Multiple Myeloma
Interventions: Melphalan, Fludarabine, Stem Cell Infusion, Rituximab; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma
Interventions: Mosunetuzumab, Polatuzumab, CAR-T Cell Therapy; Drug · Biological
Lead sponsor: Lazaros Lekakis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Candidemia, Candidiasis, Invasive
Interventions: Fosmanogepix, Caspofungin, Fluconazole, Placebo; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions: Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2, Carboplatin AUC 5; Biological · Drug
Lead sponsor: CatalYm GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 4 more

Conditions: PD-L1-selected Solid Tumors
Interventions: Tiragolumab and Atezolizumab IV FDC; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: [11C]UCB-J, Brivaracetam, Levetiracetam; Radiation · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Non-small Cell Lung Cancer
Interventions: BNT326, Pumitamig; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more

Conditions: Kidney Transplantation
Interventions: CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia, Multiple Myeloma
Interventions: Rituximab, Conditioning chemotherapy, TMS, FLAG, EPOCH-F, Hematopoietic stem cell transplant, Palifermin, Acetaminophen, Diphenhydramine, Prednisone, Epinephrine, IV Saline, ECG, ECHO, MUGA, DEXA, CT chest, PET, MRI, BM aspirate, BM biopsy, Lumbar puncture; Biological · Drug · Procedure + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib, Fulvestrant, Goserelin; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Healthy
Interventions: PF-06439535, Avastin; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Non-squamous NSCLC, HER2 Exon 20 Mutation
Interventions: Pyrotinib, Docetaxel; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Orange, California • Sacramento, California • Whittier, California + 8 more

Search by objective public record fields.

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors

A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Non-Invasive Characterization in Cardiac Sarcoidosis

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors

The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

FM 140 vs FM100 Study in Patients With Multiple Myeloma

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy